Introduction
============

Adenocarcinoma (ADC) arising in Barrett's oesophagus (BO) represents the most common oesophageal cancer. Its incidence has dramatically and rapidly increased compared to other malignancies, in both the United States \[[@b1], [@b2]\] and other western countries \[[@b3]\]. About 60% of newly diagnosed oesophageal cancers are ADC. BO is the only known histologic precursor of oesophageal ADC \[[@b4]\] and represents the major risk factor for the development of cancer. Oesophageal ADC is a highly aggressive neoplasia with disappointingly low survival rates. At the time of diagnosis, more than 50% of patients display metastatic or unresectable disease. Moreover, a high risk for recurrent disease is present after oesophagectomy or radical chemoradiotherapy. Thus, early detection and complete surgical resection represent the only strategy to cure oesophageal cancer \[[@b2]\].

Identification of neoplastic precursor lesions is, therefore, the mainstay of most surveillance and preventive programs. Histopathologic grading of dysplasia in BO is the standard method of risk stratification \[[@b5]--[@b7]\]. However, the heterogeneous behaviour of dysplasia must be taken into account; in fact, some cases progress to ADC \[[@b8]\], whereas others regress or remain stable for long periods of time after anti-reflux surgery \[[@b9]\]. For this reason, an accurate and reliable estimate of risk of progression to cancer is difficult to obtain.

The current state of knowledge includes several somatic genetic risk factors that correlate with an increased risk (relative risk \> 10) in prospective trials \[[@b10]\], such as LOH in p53 and the presence of aneuploid and tetraploid (4N fraction \>6%) cells, all of which provide a detection window of risk stratification extending at least to 5 years for most patients \[[@b11], [@b12]\]. More recently, a retrospective longitudinal study of epigenetic biomarkers, including methylation of p16, RUNX3 and HPP1, has been reported \[[@b13]\].

The role of the Her2/neu oncogene as a prognostic and predictive factor has been extensively investigated in several human neoplasms \[[@b14]\]. However, less information is available concerning the role of Her2 in the carcinogenesis process. Her2 has been found to be overexpressed/amplified in several dysplastic conditions, including bronchial and cervical dysplasia. In bronchial dysplasia, Her2 increases epithelial proliferation, but it does not seem to have a central role in the progression from dysplasia to invasive carcinoma \[[@b15]\].

Recently, it has been reported that Her2 overexpression/amplification is present in dysplasia of BO \[[@b16]\]. This prompted us to investigate the value of Her2 overexpression/ amplification in the Barrett's dysplasia-carcinoma sequence (conversion from precursor lesion to ADC in this condition).

Patients and methods
====================

Patient selection, clinical and endoscopic evaluation
-----------------------------------------------------

We retrospectively analysed clinical records and histological specimens of patients with a confirmed diagnosis of BO or oesophageal dysplasia observed at University of Brescia between 1995 and 2005. The study cohort consisted of 21 patients, 11 of which progressed to a higher-grade lesion and 10 did not. All patients underwent endoscopic surveillance according to suggested surveillance strategy programs \[[@b17], [@b18]\]. Four biopsies were performed on each centimetre of BO and where visible lesions were present, following standardized instructions for the correct orientation of the biopsies on the filter paper for histopathological assessment, to avoid tissue sampling errors \[[@b17]\]. Endoscopic mucosectomies were carried out according to previously described methods \[[@b19], [@b20]\] when dysplasia was documented on BO visible lesions, according to commonly accepted criteria \[[@b21]\].

The clinical variables analysed included age (\<65/≥65 years), gender, alcohol and smoking intake, presence of symptoms and endoscopic features (BO length \<3/≥3 cm).

The Her2 status was studied by immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH), on paraffin-embedded tissue. Numerical alterations of chromosome 17 (CEP17) were also evaluated by FISH.

Pathological evaluation
-----------------------

Immediately after sampling, the specimens were fixed in 10% neutral-buffered formalin for 24 hrs, then were included in paraffin and stained with haematoxylin-eosin (H&E) and Alcian-PAS for routine histological examination. H&E-stained slides from the resection specimens were evaluated for identification of the steps in cancer progression. ADC and precursor lesions (low-grade dysplasia, LGD; high-grade dysplasia, HGD) were diagnosed according to the WHO classification \[[@b22]\], as previously reported \[[@b23], [@b24]\]. The Her2 status was studied by immunohistochemistry (IHC) and FISH, on paraffin-embedded tissue. Numerical alterations of chromosome 17 (CEP17) were also evaluated by FISH.

Immunohistochemistry
--------------------

Her2 receptor status was studied using the HercepTest® kit (DAKOCytomation, Carpinteria, CA, USA). Following the manufacturer's recommendations, tissue sections mounted on slides and stored at room temperature (25°C) were stained within 4--6 weeks from sectioning, in order to maintain the anti-genicity, then the samples were counterstained with Mayer's haematoxylin. Her2 oncoprotein expression was evaluated by two observers, following the score system suggested by the manufacturer \[[@b25]\] and the FDA guidelines. The immunoreaction was scored as follows: 3+= complete and intense membrane staining of \>10% cells; 2+= complete but moderate staining of \>10% cells, 1+= weak and incomplete staining in \>10% cells; 0 = no membrane staining, or staining in \<10% cells.

FISH and score for HER-2/neu
----------------------------

A FDA approved kit (PathVysion HER-2 DNA Probe Kit, Vysis Inc., Downers Grove, IL, USA) was used, according to the manufacturer's recommendations. The kit consists of directly labelled fluorescent DNA probes specific for the HER-2/neu gene locus (17q11.2-q12) and a DNA probe specific for the alpha satellite DNA sequence at the centromeric region of chromosome 17 (17p11.1-q11.1). Counterstaining of nuclei was performed using DAPI (4,6-diamidino-2-phenylindole). A special amplification pattern as HER-2/neu 'signal clusters', usually with more than 10 confluent signals, was observed, as previously described \[[@b26], [@b27]\]. Although a gene amplification as 'homogeneously stained regions' is clearly evident, this pattern does not allow a precise signal enumeration. Thus, the whole area of each neoplastic lesion present in the tissue section was independently evaluated by two investigators (ER, VV) with a fluorescence microscopy (Nikon Optiphot-2, Florence, Italy) equipped with selective filters for the fluorochromes used, in high power fields (HPF; magnification 600×). FISH images were captured and elaborated using Genikon software (Nikon Instruments S.p.A, Florence, Italy). The HER-2/neu gene locus was classified as amplified if there were more than twice the number of red (Spectrum Orange labelling) HER-2/neu signals than green (Spectrum Green labelling) centromere 17 signals (ratio \>2:1) per cell nucleus. The presence of more than two nuclear red signals accompanied by the same number of nuclear green signals was considered to be indicative of polisomy of chromosome 17 (ratio 1:1). Following these accepted criteria \[[@b28], [@b29]\] the cell population of each HPF was classified as displaying a disomy, a polisomy or an amplification for HER-2/neu gene.

Statistical analysis
--------------------

This study was designed to verify whether Her2 had any influence on progression of Barrett's dysplasia-carcinoma sequence. Therefore, the occurrence of progression event was considered the statistical end-point and the time during which the progression occurred was identified as the time-to-progression (TTP), and was calculated from the time of initial histologic lesion to the first detection of a worst pathological pattern. We investigated whether clinical and pathological variables were associated with progression. Variables included age (\<65/≥65 years), gender, alcohol and smoking intake, presence of symptoms (pyrosis *versus* pyrosis and dysphagia), histology at diagnosis (BO *versus* LGD/HGD/ADC), HER2 status according to IHC (0--2 *versus* 3) and FISH (not amplified *versus* amplified) and endoscopic features (BO length \<3/≥3 cm). The cut-off value of 65 years was chosen according to the median value of this series (median age 63 years) and we adopted the international cut-off value of 3 cm for BO length. These two variables were considered continuous while all the others were categorized. The chi-square test or the t-test were used, where appropriate, to test associations of single variables in two-way tables. *P-*values of 0.05 or less were chosen to reject the null hypothesis. Statistically significant variables at univariate analysis were then tested for their effect on the TTP, *i.e.* if they were associated to a faster progression. To do this, TTP curves according to covariates were estimated by the Kaplan--Meier method and differences between curves were analysed using the log-rank test. Statistical analysis was done by means of the (SPSS Inc., Chicago, IL, USA) 12.0 software package.

Ethical considerations
======================

Because this was a retrospective study, no individual patient identification was involved and no study-driven clinical intervention was performed. Thus, a simplified Institutional Review Board approval for retrospective studies was obtained and no patient consent was considered necessary.

Results
=======

Patient population
------------------

The study population included 21 patients (16 men and 5 women, median 63 years \[range 37--84\]) for whom adequate clinical follow-up information and histological samples were available. Demographic, endoscopic and histologic features of these patients are shown in Table [1](#tbl1){ref-type="table"}. BO median length was 4.5 cm (range 2--10); 11/21 (52.4%) patients had a BO length ≥3 cm and 8 of them underwent neoplastic transformation.

###### 

Clinical and pathological features and univariate analysis of prognostic factors for TTP

  Feature                                    *n*   Chi-square test
  -------------------------- --------------- ----- -----------------
  Age                        \<65 years      11    0.75
  \>65 years                 10                    
  Gender                     Male            16    0.90
  Female                     5                     
  Smoke                      Yes             7     0.73
  No                         14                    
  History of alcohol abuse   Yes             4     0.65
  No                         17                    
  Symptoms                   Pyrosis         17    0.24
  Pyrosis + dysphagia        4                     
  BO length                  \<3 cm          10    0.09
  \>3 cm                     11                    
  HER2 (IHC)                 0−2             13    0.04
  3+                         8                     
  HER2 (FISH)                Not amplified   14    0.04
  Amplified                  7                     
  CEP17                      Disomic         16    0.65
  Polysomic                  5                     
  Histology                  BO              13    0.04
  LGD+HGD                    8                     

Abbreviations: CEP 17, chromosome enumeration probe

BO, Barrett's oesophagus

FISH, fluorescence *in situ* hybridisation

IHC, immunohistochemistry.

All patients were treated with proton pump inhibitors, and 7 of them (33%) underwent laparoscopic fundoplication for symptoms unresponsive to medical treatment. Six of 21 (29%) patients were smokers, while alcohol abuse was documented in 17 of 21 (81%) patients. All patients complained of pyrosis, whereas dysphagia was present in 3 of 21 (14%) patients. After a median follow-up of 36 months (range 12--120), all patients are alive.

Initial presentation included BO in 13 patients, LGD in 7 patients, HGD in 1 patient. Progression occurred in 11 of 21 (52%) patients and median TTP was 24 months (range 12--120). At the evaluated end-point (progression), we recognized 9 BO, 2 LGD, 4 HGD and 6 ADC (Table [2](#tbl2){ref-type="table"}).

###### 

Analysis of progression of oesophageal pre-neoplastic lesions in function of time

  Patient \#   Initial diagnosis   HER-2 amplification(FISH)/ overexpression (IHC)   Progression (yes/no)   Final diagnosis   HER-2 amplification(FISH)/ overexpression (IHC)   TTP or max follow-up time (months)   Status at follow-up
  ------------ ------------------- ------------------------------------------------- ---------------------- ----------------- ------------------------------------------------- ------------------------------------ ---------------------
  1            BO                  NA / 0                                            Yes                    LGD               A / 3+                                            120                                  Alive
  2            LGD                 A / 3+                                            Yes                    ADC               A / 3+                                            12                                   Alive
  3            LGD                 A / 3+                                            Yes                    HGD               A / 3+                                            24                                   Alive
  4            LGD                 A / 3+                                            Yes                    ADC               A / 3+                                            24                                   Alive
  5            LGD                 A / 3+                                            Yes                    ADC               A / 3+                                            120                                  Alive
  6            BO                  NA / 0                                            Yes                    ADC               NA / 1+                                           48                                   Alive
  7            LGD                 A / 3+                                            Yes                    ADC               A / 3+                                            12                                   Alive
  8            LGD                 A / 3+                                            Yes                    HGD               A / 3+                                            24                                   Alive
  9            BO                  NA / 1+                                           Yes                    ADC               NA / 1+                                           60                                   Alive
  10           LGD                 NA / 1+                                           Yes                    HGD               NA / 1+                                           24                                   Alive
  11           BO                  NA / 1+                                           Yes                    LGD               NA / 1+                                           36                                   Alive
  12           BO                  NA / 1+                                           No                     BO                NA / 1+                                           48                                   Alive
  13           BO                  NA / 1+                                           No                     BO                NA / 1+                                           96                                   Alive
  14           HGD                 A / 3+                                            No                     HGD               A / 3+                                            12                                   Alive
  15           BO                  NA / 0                                            No                     BO                NA / 0                                            36                                   Alive
  16           BO                  NA / 1+                                           No                     BO                NA / 1+                                           36                                   Alive
  17           BO                  NA / 1+                                           No                     BO                NA / 1+                                           24                                   Alive
  18           BO                  NA / 0                                            No                     BO                NA / 0                                            60                                   Alive
  19           BO                  NA / 2+                                           No                     LGD               NA / 2+                                           72                                   Alive
  20           BO                  NA / 1+                                           No                     BO                NA / 1+                                           48                                   Alive
  21           BO                  NA / 0                                            No                     BO                NA / 0                                            72                                   Alive

Abbreviations: BO, Barrett's oesophagus

LGD, low-grade dysplasia

HGD, high-grade dysplasia

ADC, adenocarcinoma

FISH, fluorescence *in situ* hybridization

IHC, immunohistochemistry

TTP, time to progression (calculated for those patients who progressed)

maximum follow-up time (calculated for non-progressors patients).

Immunohistochemical and FISH analysis of Her2 expression
--------------------------------------------------------

Overall, a 100% positive correlation was found between Her2 gene amplification and protein overexpression score 3+. Her2 was overexpressed/amplified in 8 of 21 (38%) cases, whereas CEP17 probe identified an aneusomy in 4 of 21 (19%). Her2 was never found amplified/overexpressed in BO alone. Its amplification/overexpression always characterized dysplasia (both LGD and HGD) and ADC (Figs [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}). Her2 resulted amplified in 7 of 11 patients whose initial dysplastic lesion progressed toward a higher grade and in 1 of 10 patients who did not progress. One out of 11 patients who progressed (patients \#1) was negative at the baseline (where it was diagnosed as BO), but after 10 years (120 months, Table [2](#tbl2){ref-type="table"}) of follow-up LGD with HER-2 overexpressed/ amplified was found. Aneusomy of chromosome 17 was detected in 4 of 21 (19%) patients in the whole series, with 3 patients who underwent neoplastic transformation and 1 who did not, respectively.

![Normal oesophagus (A) and Barrett's oesophagus (B) display a normal pattern of HER-2/neu protooncogene (red spots) and chromosome 17 probe (green spots). On the other hand, in LGD (C) and in HGD (D) the HER-2/neu gene is amplified (amplification if the ratio between HER-2/neu signals and CEP17 signals is \>2) (original magnification, ×40).](jcmm0013-3826-f1){#fig01}

![Area of metaplasia (Barrett's oesophagus) and dysplasia stained for HER-2 by immunohistochemistry. It is possible to recognize the different expression of HER-2: completely negative in BO and overexpressed in the areas of dysplasia. Original magnification, ×40).](jcmm0013-3826-f2){#fig02}

Analysis of prognostic factors
------------------------------

At univariate analysis, HER2 overexpression/amplification (*P*= 0.038) and the existence of LGD or HGD at diagnosis (*P*= 0.038) were the only variables significantly associated with the occurrence of progression. BO length did not reach statistical significance (*P*= 0.088) like aneusomy of chromosome 17 (*P*= 0.652) and age (*P*= 0.756) (Table [1](#tbl1){ref-type="table"}). Among patients who progressed, the median TTP was shorter (TTP = 24 months) in Her2 positive group than in the Her2- one (TTP = 48 months) although this was not statistically significant (log-rank test *P* \> 0.08).

Discussion
==========

The ultimate goal of cancer surveillance and prevention programs is to identify those patients at high risk of developing a certain cancer, in order to treat the precursor condition, or to identify the invasive cancer at a very early stage. Concerning oesophageal ADC, the identification of intestinal metaplasia, *i.e.* BO, and dysplasia represents the major risk factor. Patients with BO have an annual incidence of oesophageal carcinoma between 0.5% and 1%. Therefore, the histopathologic classification of the grade of dysplasia in BO is the only currently accepted method for risk stratification of patients. However, progression from one lesion to another and to cancer typically occurs with a long latency \[[@b4]\] and shows considerable to eliminate heterogeneity. Thus, identification of different dysplastic conditions is a poor predictor of which patient and how rapidly he/she will ultimately progress to cancer.

We investigated whether an increased expression of Her2 might contribute to the development and progression of oesophageal dysplasia. Our results show that Her2 amplification/overexpression is correlated to dysplasia (LGD or HGD) and with progression to a more advanced step (HGD or ADC); in fact, we found that TTP was shorter in HER-2 positive group than in HER-2 negative group. Thus, we cannot rule out a definitive causative role for HER2 in the pathogenesis of oesophageal ADC for which further studies and larger series of patients are required.

The median TTP in our series was 24 months; this was shorter than that reported in other countries, 4--8 years \[[@b30], [@b31]\], even though data from our country suggest that the TTP for the Italian population may be shorter with respect to other populations \[[@b7]\].

Because metaplastic/dysplastic lesions of different grade often coexist in the same histological sample, we selected patients in which only one precursor lesion was present, or at least predominant. This allowed us to identify the role of Her2 in each individual step of the sequence. Consistent with previous reports, we were not able to identify Her2 alterations in BO alone \[[@b16]\], whereas its amplification/overexpression was first detected in LGD patients and was constitutively present up to ADC.

It is worth noting that FISH data overlapped those obtained from IHC 3+ scores (100% positive correlation) at the initial (7/7 cases) and the final (8/8 cases) step. The effect of analysing Her2 status by either FISH or IHC has been extensively reviewed \[[@b32]--[@b35]\], confirming that FISH provides a more powerful prog-nostic indicator.

Case \#1 represents a peculiarity, because at baseline it was classified as BO negative for HER2 (both IHC and FISH), whereas at the final step (after 10 years) we found HER-2-positive LGD. This case was included because: (1) the patient took time to develop dysplasia, probably because at the beginning BO was HER-2-negative (not overexpressed nor amplified); (2) at present this patient shows LGD positive for HER-2 (overexpressed and amplified), and for this reason we hypothesize that the progression to the subsequent steps (HGD-ADC) could be faster and requires a closer follow-up.

The aneusomy of chromosome 17 did not have influence on BO progression (*P*= 0.65), probably because of the small size of our series. This was, however, a surprising finding because DNA aneuploidy/aneusomy is a recognized marker of cancer progression \[[@b36]\] and chromosome 17 copy number increases through cancer progression \[[@b20]\]. However, even though in our study chromosome 17 aneusomy was not correlated to a faster development of the neoplasm, these results are not in contrast with literature. Clinically, it is still uncertain whether an increase in Her2 copy number alone or an increase of the Her2 copies/chromosome 17 copies ratio is more useful in predicting the outcome. A recent report in breast cancer suggested that increased Her2 gene dosage may be the most important determinant of Her2 gene expression, whereas that resulting from polysomy 17 alone is rather unlikely to significantly contribute to Her2 overexpression \[[@b37]\].

Among clinical features, neither age nor the presence of dysphagia were significant variables. All patients had a previous history of pyrosis, and the association of dysphagia could represent a clinical indicator of an aggressive evolution. In our series, BO length (a well-recognized risk factor of progression of BO to ADC \[[@b38]\]) did not reach statistical significance but showed a positive correlation with progression.

The clinical significance of Her2 both as a prognostic factor and as a therapeutic molecular target is well-recognized in breast cancer \[[@b39], [@b40]\]. However, only a few reports exist concerning its role in precursor conditions, including bronchial, cervical and vulvar dysplasia \[[@b15], [@b41], [@b42]\]. In these reports, Her2 alterations were not found to be the major pathogenetic hallmark of the condition, but were related to higher proliferation index and contributed to a more malignant phenotype.

This is the first report describing a potential critical role for Her2 in the pathogenesis of oesophageal carcinoma. Although this study reports on a small series and validation is required on a larger analysis, we feel that several points merit attention: (1) Her2 is associated with distinct stages of dysplasia arising in BO; (2) Her2 is associated with the progression of dysplasia and shows a trend toward a shorter TTP.

As other studies (evaluating the role of Her2 in brush cytology from BO patients) are appearing in literature, and are also consistent with our results \[[@b43], [@b44]\], this should prompt further research into Her2 role in the pathogenesis of oesophageal ADC, to establish whether this is a potential biomarker with prognostic significance and a putative candidate for targeted chemoprevention \[[@b45]\].
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